All Updates

All Updates

icon
Filter
Funding
Listing
Cargo Therapeutics debuts in Nasdaq to raise USD 281 million
Cell & Gene Therapy
Nov 10, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Nov 10, 2023

Cargo Therapeutics debuts in Nasdaq to raise USD 281 million

Funding
Listing

  • California-based CAR T-cell therapy company Cargo Therapeutics began trading on the Nasdaq Global Select Market on November 10, 2023, under the ticker symbol “CRGX.” It has priced its public offering of 18.75 million common shares at USD 15 per share, amounting to gross proceeds of USD 281.3 million.

  • The company has also granted a 30-day purchase option on an additional 2.8 million shares to underwriters at the same price less discounts and commissions. The offering window is expected to close on November 14, 2023.

  • The proceeds from the offering will be used to fund a Phase II clinical trial of its lead candidate, CRG-022, for the treatment of large B-cell lymphoma.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.